Matthew A. Gill

Internal Medicine
24400 Greater Mack Ave
Saint Clair Shores, MI 48080

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1 publications

GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer.

GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer.

Journal: Journal of medicinal chemistry
Published: July 12, 2021
Showing 1-1 of 1

Last Updated: 09/26/2026